Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
about
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersBehavioural treatments for non-epileptic attack disorderCombined psychotherapy plus antidepressants for panic disorder with or without agoraphobiaCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersDifferences in symptom structure between panic attack and limited symptom panic attack: a study using cluster analysisParoxetine efficacy in the treatment of generalized anxiety disorderIntimacy disorders and sexual panic statesPsychopharmacological AgentsNew developments in panic disorder.Management of anxiety disorders: the added challenge of comorbidity.Anxiety disorders and major depression, together or apart.Differential diagnosis and treatment of the "housebound syndrome".World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Pharmacotherapy of anxious disorders.Sleep and anxiety disorders.Panic Disorder and Chest Pain: Mechanisms, Morbidity, and Management.Strategies for the drug treatment of depression.Treatment-resistant panic disorder.Clinical and biochemical aspects of depressive disorders: III. Treatment and controversies.Management of panic disorder.Panic disorder. Recognizing and managing the 'real thing'.Sleep disturbance in anxiety disorders.Panic attacks and panic disorders.Differentiating endogenous panic/anxiety disorders from dental anxietyOverview of panic disorder.Treatment of anxiety.Management of panic disorders.Anxiety, depression, and substance use disorders: diagnosis, treatment, and prescribing practices.A pilot placebo-controlled, double-blind, and randomized study on the cognition-enhancing benefits of a proprietary chicken meat ingredient in healthy subjects.Sleep disturbance and emotion dysregulation as transdiagnostic processes in a comorbid sample.Serotonin selectivity for obsessive compulsive and panic disordersA review of the psychopharmacology of panic disorder: individual differences and non specific factors.Monoamine oxidase inhibitors: clinical review.Drug treatment of panic disorder.Evidence-based pharmacotherapy of panic disorder: an update.Alcoholism and panic disorder: is the comorbidity more than coincidence?Obstructive sleep apnea and severe mental illness: evolution and consequences.Rediscovering monoamine oxidase inhibitors.The classification of phobic disorders.The utility of the panic disorder concept.
P2860
Q22305681-A53BEC97-58B2-4103-B1B0-E15F37C7908EQ24243183-B78B8050-AA91-4347-980F-C06026B49168Q24243197-580D6859-0B76-4F1D-AC74-4433FD48F4C5Q27009995-AB438312-657D-4702-84BD-515673690CD2Q28237371-61886C80-31D7-41B9-B41E-B81C09F36402Q28241959-6BD5C15A-A985-41AF-9785-FD369A9A6150Q29396458-9789A5CC-4AE1-4EE3-B6F9-943D27751743Q29998990-542BB6E0-0BF0-4766-84E2-0E6490AC7344Q34108487-C2600F71-1166-47D9-BA0D-C7F2B3951F30Q34218830-7BEAC25C-48A7-4622-A5D8-482F5F85FE62Q34415535-0C2CAD4B-98DC-4731-BC2B-E7CF75E7BCA1Q34700308-316BEB5A-597B-42FD-9335-F47D069831E0Q34865036-6397E85C-D072-4A6C-8412-38C4BBCC60E4Q35011794-A53F85B9-AA3F-4184-AF4D-B4BCCDF52494Q35236342-90680E42-0639-4F90-B408-5E460ED0AF91Q35667037-37D28B32-05A7-4510-9ACF-32D196727528Q35807745-6F003BC2-AAA4-4B24-A18A-DA6E09690514Q35901886-7FCF301E-4BE2-4E12-8920-F873B95787E8Q36106487-DE02DD4D-1E6C-4BCE-9226-37718996F7CFQ36106827-EAEB17B2-79BC-4F73-B775-542FB7E96B8BQ36127525-5E46FA5C-58F7-49D7-9543-24D1EB7F5830Q36272523-529AAD20-AA8D-4A64-8C12-7AACFF49A367Q36298264-26CE6AC6-96D1-4CCB-B616-72AB68FA3070Q36360508-956816BD-86EE-40CC-AE2F-5569C2789DA9Q36647657-93919BC2-07D6-4DC3-81CB-DC10A732D44DQ36886842-083C84A6-F910-4983-83E8-EB2CB07C3CDEQ37042373-9DB7C3CD-8720-436D-B3F6-531FD588D1ABQ37042411-100D0D9E-1C97-45A8-AF39-3D8933A7C8C6Q37153322-C14F775E-F72E-4ABA-B5B7-EE92A25A7813Q37176241-84DFA49A-23B7-4E9E-8F82-03C901427A40Q37423109-A8AC0F12-AE30-4F76-9E50-F80235D3FBD2Q37741811-0A02501E-E692-4FDE-9183-B81C52089B5CQ37828375-0344A919-ED1C-44E3-AFC3-F1D5D7DF3BDBQ37884709-6DE09182-D52A-4D06-BE83-D728E5DABEA2Q37898209-0ADE1CDE-8419-401F-BAC8-0277DC88B59EQ37915749-4AFE67AF-F42B-4B15-A789-56181E0E39E6Q38032813-1BB4A469-C967-4D06-9E40-386C34ED58B6Q38221074-5B1CBA04-426E-4B95-A318-F3652D7E8414Q38578151-81BD72B5-C417-4E0E-AFCF-33113925D3EFQ38679854-7C11B467-5370-47FD-8317-E3ADBA0AAD9B
P2860
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年学术文章
@wuu
1980年学术文章
@zh
1980年学术文章
@zh-cn
1980年学术文章
@zh-hans
1980年学术文章
@zh-my
1980年学术文章
@zh-sg
1980年學術文章
@yue
1980年學術文章
@zh-hant
name
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
@en
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
@nl
type
label
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
@en
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
@nl
prefLabel
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
@en
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.
@nl
P1433
P1476
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms
@en
P2093
G Jacobsen
J Ballenger
P356
10.1001/ARCHPSYC.1980.01780140053006
P407
P577
1980-01-01T00:00:00Z